PTSB's €2.97 Buyout Is Nearly Priced In — What the Form 8.3 Filings Reveal

For most investors, "Form 8.3" reads like a piece of mechanical noise — a regulator's form number, the kind of thing that scrolls past on a terminal. It is doing real work. Under the UK and Irish Takeover Codes, anyone who holds at least 1% of a company in a bid must file a Form 8.3 every time they buy or sell, forcing every meaningful position to be stamped into the public record. A takeover does not run on rumors; it runs on a paper trail, and the Form 8.3 is where that trail becomes visible to anyone willing to count.

That trail is currently thick around one Irish bank, and reading it correctly changes what an investor sees in the stock.

The deal the filings are tracking

Permanent TSB Group Holdings (PTSB) is a Dublin-based retail and SME bank, founded in 1816, that carries the scars of the 2008 crisis: the Irish state still owns 57.5% of it. On 14 April 2026, the Austrian lender BAWAG agreed a recommended all-cash offer of €2.97 per PTSB share — about €1.6 billion for the whole company, and roughly €931 million of it owed to the state's stake. The board endorsed it after a formal sale process the bank launched on 30 October 2025. For the state, this is the end of a seventeen-year exit: the last Irish bank holding from the crisis goes to a foreign buyer.

The best measure of the premium is the one BAWAG itself gave. Compared with the undisturbed closing price of €2.35 the day before the sale process began, the offer is 26% higher; against the six-month average share price, 45%; against the twelve-month average, 71%. Whatever the window, the bidder paid up to own PTSB, and the reason is the state's willingness to sell at the end of a crisis-era exit.

Where the deal stands now

The deal has cleared the two easy hurdles. The Irish competition authority (CCPC) gave its clearance in June 2026, and on 30 July 2026 shareholders voted in favour at the scheme meeting and EGM. Two conditions remain: approval from the European Central Bank and the sanction of the Irish High Court. Completion is targeted for the fourth quarter of 2026 or the first quarter of 2027. Until those two boxes are ticked, the bid stays formally open — and every fund holding a 1% stake keeps filing its Form 8.3. Barclays and the quant house Qube Research filed theirs in early September. The filings do not announce the deal; they announce that the deal is still alive and still being tested.

The two cents that tell you the premium is gone

Here is the number that the disclosure blizzard makes legible. PTSB trades today at roughly €2.95 — about two cents below the €2.97 offer. A stock in a friendly, recommended, fully-regulated cash bid drifts toward the offer price as completion looks more certain, because the spread between price and offer is what an arbitrageur earns for taking closing risk. That spread is now about 0.7%. The market has effectively decided that ECB sign-off and a High Court order are formalities, and it is paying holders almost nothing to wait through them.

That is also the moment the situation stops being an opportunity and becomes a piece of arithmetic about who is actually being paid. The 26% to 71% premium was the reward for one of two people: the owner who held before the deal was announced, or the patient investor who sat through the months of the sale process. Anyone buying PTSB at today's price collects the same €2.97 currency, but their premium is gone — they are buying a 0.7% gross spread, carrying the full cost of the two approvals and the schedule slip into 2027 if either one drags. A sub-1% annualized return is not compensation for the event that the deal shocks — the various, if remote, ways a recommended bid can still break.

The asymmetry is quietly large. Below today's price sits a whole history of what PTSB was worth before BAWAG's interest became public: the twelve-month average share price was €1.74, and the stock spent much of the past year in the low-to-mid €2s. The 52-week range reaches as low as €2.10 on one side and spiked to €3.34 during the period when a bid looked likely. A holder who got in during those low months is sitting on a realized gain the moment the scheme closes. A buyer who arrives now has upside of two cents and, if completion collapses, downside to a banking stock with no takeover premium in it at all.

What the disclosure machinery is actually worth

The honest reading of this case is that the detective work is done — and that is precisely the information the Form 8.3 pipeline provides. In an opaque company, an unexplained gap between profit and cash is a red flag that asks a question. Here the takeover code performs the opposite function: it compels the discloser to answer every question in advance, publishing every material position and every deal. There is no hidden counterparty and no missing cash. The transparency is the product, and the price pin is its confirmation. Where the sale of a distressed company leaves the buyer guessing, a regulated, recommended all-cash bid hands the minority shareholder a nearly fixed outcome — the €2.97, the premium basis, and the remaining conditions all on the table.

That clarity is what makes the final judgment unforgiving. The shareholder invoice for anyone already positioned is closed out at €2.97, and the only open question is timing: whether the ECB and the court deliver in Q4 2026 or let the completion slip into Q1 2027. The invoice for anyone joining now is different — two cents of spread in exchange for bearing a completion risk the market has already priced as near zero. The Form 8.3s say the deal is real, regulated, and likely to close. They do not manufacture an opportunity out of it for a new buyer. The premium was the property of the people who were already there.